COR vs the Top Picks average
| Pillar | COR | Book avg | Diff |
|---|---|---|---|
| Quality | 69 | 83 | -14 |
| Growth | 73 | 89 | -16 |
| Value | 48 | 76 | -28 |
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
One point per daily run; read From → To for the actual range.
COR at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
| 30-day change | -0.0% |
|---|---|
| 90-day change | -0.0% |
| Forward EPS estimate | $19.80 |
Over the last 90 days, what analysts expect COR to earn is essentially unchanged. The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
Cencora, Inc. (COR): score, valuation & FAQ
Cencora, Inc. (COR) is a Medical Distribution company that scores 62.1 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (A-) and P/E (B+), while D/E (D) rate weaker. On valuation, COR sits about 41% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow shrinking about 5% next year, then recovering toward 4% a year by year ten.
Is COR a good stock to buy?
Bull Rankings scores COR 62.1 out of 100 on its quality-growth model, which is a middling reading. That is driven by PEG (A-) and P/E (B+). A score is a quantitative screen of Cencora, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does COR score 62.1 on Bull Rankings?
The score leans on growth at 72.8 out of 100, with value the weakest pillar at 47.8 — the three combine geometrically, so a weak one cannot be papered over by a strong one. COR earns its highest marks on PEG (A-) and P/E (B+), and is held back by D/E (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so COR is measured against Medical Distribution peers, not against the market as a whole.
Is COR overvalued or undervalued?
Based on $323.85, COR sits about 41% below our discounted-cash-flow fair value (a margin of safety) — the current price implies free cash flow shrinking about 5% next year, then recovering toward 4% a year by year ten. It trades at a 24.0x P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in COR?
D/E 4.47 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 0.8% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
New to these metrics? See the guides and the methodology.